4th October 2019, Volume 132 Number 1503

Marta Rychert, Chris Wilkins, Geoff Noller

The Ministry of Health (MOH) recently released a consultation document outlining proposals for the New Zealand Medicinal Cannabis Scheme (NZMCS) and completed a series of public consultations seeking feedback from…

Subscriber content

The full contents of this page is only available to subscribers.

To view this content please login or subscribe

Author Information

Marta Rychert, SHORE & Whariki Research Centre, College of Health, Massey University;
Chris Wilkins, SHORE & Whariki Research Centre, College of Health, Massey University;
Geoff Noller, Department of General Practice and Rural Health, School of Medicine, University of Otago.

Correspondence

Marta Rychert, SHORE & Whariki Research Centre, College of Health, Massey University.

Correspondence Email

m.rychert@massey.ac.nz

Competing Interests

Conflict of interests: MR and CW are currently conducting a study of medicinal cannabis use funded by the Health Research Council (19/647) and Massey University Research Fund. GN is conducting a study of medicinal cannabis use funded by Medical Cannabis Awareness New Zealand (MCANZ), a medical cannabis patient advocacy organisation.

References

  1. Ministry of Health. Medicinal Cannabis Scheme: Consultation document. Wellington 2019. http://www.health.govt.nz/publication/medicinal-cannabis-scheme-consultation
  2. Newton-Howes G, McBride S. Medicinal cannabis: moving the debate forward. NZMJ 2016; 129(1445):103–9.
  3. Wilkins C. The case for medicinal cannabis: where there is smoke there may well be fire. NZMJ 2016; 129(1445):11–4.
  4. Braithwaite I, Newton-Howes G, Oldfield K, Semprini A. Cannabis-based medicinal products and the role of the doctor: should we be cautious or cautiously optimistic? NZMJ 2019; 132(1500):82–8.
  5. Satherley D, Prendergast E. Medicinal cannabis users call for amnesty ahead of law change (11 July 2019). Newshub; 2019. Available from: http://www.newshub.co.nz/home/politics/2019/07/medicinal-cannabis-users-call-for-amnesty-ahead-of-law-change.html
  6. Horizon Poll. Specialist sign-off for cannabis would strain health sector (2 August 2019). Results from Horizon Poll survey commissioned by Helius Therapeutics. http://www.horizonpoll.co.nz/page/549/specialist-shttp://www.tga.gov.au/access-medicinal-cannabis-products-1
  7. Therapeutic Goods Administration. Access to medicinal cannabis products. (5 August 2019). 2019.
  8. Victoria State Government. Information for Health Professionals 2019. http://www2.health.vic.gov.au/public-health/drugs-and-poisons/medicinal-cannabis/health-professionals
  9. Rychert M, Wilkins C. Did we have the wrong debate about Elixinol™ and medicinal cannabis? NZMJ 2015; 128(1421):69–70.
  10. Hazekamp A. The Trouble with CBD Oil. Medical Cannabis and Cannabinoids. 2018; 1(1):65–72.
  11. MILDECA (Interministerial Mission for Combating Drugs and Addictive Behaviours). Cannabidiol (CBD) le point sur la législation. (11 June 2018). 2019. http://www.drogues.gouv.fr/actualites/cannabidiol-cbd-point-legislation
  12. Hasse J. This EU Country Has Become The First To Allow Free Sale Of CBD. (23 May 2019). Forbes; 2019. http://www.forbes.com/sites/javierhasse/2019/05/23/this-eu-country-has-apparently-become-the-first-to-allow-free-sale-of-cbd/#714ec5cc36c9
  13. Food and Drug Administration. FDA is Committed to Sound, Science-based Policy on CBD. (17 July 2019) http://www.fda.gov/news-events/fda-voices-perspectives-fda-leadership-and-experts/fda-committed-sound-science-based-policy-cbd
  14. MOH. Review of the Psychoactive Substances Act 2013. (14 January 2019) http://www.health.govt.nz/publication/review-psychoactive-substances-act-2013 Archived by WebCite at: http://www.webcitation.org/75v07Ru8I
  15. Rychert M, Wilkins C. New Zealand’s review of the Psychoactive Substances Act 2013: a missed learning opportunity ahead of the national cannabis law reform referendum? Addiction. 2019; 114(6):1129–30.
  16. Rychert M, Wilkins C. A critical analysis of the implementation of a legal regulated market for new psychoactive substances (“legal highs”) in New Zealand. IJDP. 2018; 55:88–94.
  17. Auckland Patients Group. A report from an attendee of the Ministry of Health Consultation scheme. (24 July 2019) http://www.facebook.com/AuckPatientGroup/posts/2727004267312623?__tn__=K-R
  18. Radio New Zealand. Medicinal cannabis regulations: Questions raised over specialist sign-off. (11 July 2019). An interview with Richard Medlicott (College of General Practitioners). 2019. http://www.rnz.co.nz/national/programmes/ninetonoon/audio/2018703643/medicinal-cannabis-regulations-questions-raised-over-specialist-sign-off
  19. Setboonsarng C. Thailand set to deliver first batch of medical marijuana. (2 August 2019) http://www.reuters.com/article/us-thailand-cannabis/thailand-set-to-deliver-first-batch-of-medical-marijuana-idUSKCN1UR4LX
  20. Cannabis Licensing Authority. License eligibility criteria. 2016. http://www.cla.org.jm/application/basic-eligibility-criteria
  21. Pledger M, Martin G, Cumming J. New Zealand Health Survey 2012/13: characteristics of medicinal cannabis users. NZMJ. 2016; 129(1433):25–36.
  22. Fergusson DM, Swain-Campbell NR, Horwood LJ. Arrests and convictions for cannabis related offences in a New Zealand birth cohort. Drug Alcohol Depen 2003; 70(1):53–63.
  23. Cannabis Licensing Authority. Alternative Development Project: including the small traditional ganja farmers in the regulated space. 2018. Available from: http://www.cla.org.jm/sites/default/files/documents/The%20Alternative%20development%20Programme_as%20at%20December%202017.pdf
  24. Office of the Minister of Justice. 2020 Cannabis Referendum - legislative process and overarching policy settings for the regulatory model. Cabinet paper. Considered by Cabinet on 6 May 2019. Released 7 May 2019. http://www.beehive.govt.nz/sites/default/files/2019-05/Proactive%20release%20-%20Cabinet%20paper%20-%202020%20Cannabis%20Referendum%20-%207%20May%202019.pdf
  25. Cox C. Medical Cannabis vs. Recreational Cannabis…. Why we need them both. 2018. http://healthlawmatters.squarespace.com/home/2019/3/18/medical-cannabis-vs-recreational-cannabis-why-we-need-them-both
  26. Cairns E, Kelly M. Why support a separate medical access framework for cannabis? CMAJ. 2017; 189(28):E927–E8.

Download

The downloadable PDF version of this article is only available to subscribers.

To view this content please login or subscribe